171 related articles for article (PubMed ID: 38447809)
21. Rational design of antibody-like peptides for targeting the human complement fragment protein C5a.
Ghosh M; Shadangi S; Rana S
Proteins; 2024 Apr; 92(4):449-463. PubMed ID: 37933678
[TBL] [Abstract][Full Text] [Related]
22. Rapid-onset clinical and mechanistic effects of anti-C5aR treatment in the mouse collagen-induced arthritis model.
Andersson C; Wenander CS; Usher PA; Hebsgaard JB; Sondergaard BC; Rønø B; Mackay C; Friedrichsen B; Chang C; Tang R; Hornum L
Clin Exp Immunol; 2014 Jul; 177(1):219-33. PubMed ID: 24665841
[TBL] [Abstract][Full Text] [Related]
23. Selective therapeutic control of C5a and the terminal complement complex by anti-C5 single-chain Fv in an experimental model of antigen-induced arthritis in rats.
Fischetti F; Durigutto P; Macor P; Marzari R; Carretta R; Tedesco F
Arthritis Rheum; 2007 Apr; 56(4):1187-97. PubMed ID: 17393439
[TBL] [Abstract][Full Text] [Related]
24. A self-assembling peptide acting as an immune adjuvant.
Rudra JS; Tian YF; Jung JP; Collier JH
Proc Natl Acad Sci U S A; 2010 Jan; 107(2):622-7. PubMed ID: 20080728
[TBL] [Abstract][Full Text] [Related]
25. A New Approach for the Treatment of Arthritis in Mice with a Novel Conjugate of an Anti-C5aR1 Antibody and C5 Small Interfering RNA.
Mehta G; Scheinman RI; Holers VM; Banda NK
J Immunol; 2015 Jun; 194(11):5446-54. PubMed ID: 25917104
[TBL] [Abstract][Full Text] [Related]
26. Complement 5a Enhances Hepatic Metastases of Colon Cancer via Monocyte Chemoattractant Protein-1-mediated Inflammatory Cell Infiltration.
Piao C; Cai L; Qiu S; Jia L; Song W; Du J
J Biol Chem; 2015 Apr; 290(17):10667-76. PubMed ID: 25739439
[TBL] [Abstract][Full Text] [Related]
27. Blockade of complement activation product C5a activity using specific antibody attenuates intestinal damage in trinitrobenzene sulfonic acid induced model of colitis.
Chen G; Yang Y; Gao X; Dou Y; Wang H; Han G; Wang R; Wang J; Wang L; Li X; Guo R; Xiao H; Shen B; Li Y
Lab Invest; 2011 Mar; 91(3):472-83. PubMed ID: 21102504
[TBL] [Abstract][Full Text] [Related]
28. Protective effects of anti-C5a peptide antibodies in experimental sepsis.
Huber-Lang MS; Sarma JV; McGuire SR; Lu KT; Guo RF; Padgaonkar VA; Younkin EM; Laudes IJ; Riedemann NC; Younger JG; Ward PA
FASEB J; 2001 Mar; 15(3):568-70. PubMed ID: 11259369
[TBL] [Abstract][Full Text] [Related]
29. Modulating adaptive immune responses to peptide self-assemblies.
Rudra JS; Sun T; Bird KC; Daniels MD; Gasiorowski JZ; Chong AS; Collier JH
ACS Nano; 2012 Feb; 6(2):1557-64. PubMed ID: 22273009
[TBL] [Abstract][Full Text] [Related]
30. Receptors for complement C5a. The importance of C5aR and the enigmatic role of C5L2.
Lee H; Whitfeld PL; Mackay CR
Immunol Cell Biol; 2008 Feb; 86(2):153-60. PubMed ID: 18227853
[TBL] [Abstract][Full Text] [Related]
31. Controlled Lengthwise Assembly of Helical Peptide Nanofibers to Modulate CD8
Fries CN; Wu Y; Kelly SH; Wolf M; Votaw NL; Zauscher S; Collier JH
Adv Mater; 2020 Oct; 32(39):e2003310. PubMed ID: 32820582
[TBL] [Abstract][Full Text] [Related]
32. A glucose-6-phosphate isomerase peptide induces T and B cell-dependent chronic arthritis in C57BL/10 mice: arthritis without reactive oxygen species and complement.
Pizzolla A; Wing K; Holmdahl R
Am J Pathol; 2013 Oct; 183(4):1144-1155. PubMed ID: 23911657
[TBL] [Abstract][Full Text] [Related]
33. Active immunization to tumor necrosis factor-alpha is effective in treating chronic established inflammatory disease: a long-term study in a transgenic model of arthritis.
Delavallée L; Semerano L; Assier E; Vogel G; Vuagniaux G; Laborie M; Zagury D; Bessis N; Boissier MC
Arthritis Res Ther; 2009; 11(6):R195. PubMed ID: 20030816
[TBL] [Abstract][Full Text] [Related]
34. Critical role of C5a in sickle cell disease.
Vercellotti GM; Dalmasso AP; Schaid TR; Nguyen J; Chen C; Ericson ME; Abdulla F; Killeen T; Lindorfer MA; Taylor RP; Belcher JD
Am J Hematol; 2019 Mar; 94(3):327-337. PubMed ID: 30569594
[TBL] [Abstract][Full Text] [Related]
35. Complement C5a Receptor 1 Exacerbates the Pathophysiology of
Herrmann JB; Muenstermann M; Strobel L; Schubert-Unkmeir A; Woodruff TM; Gray-Owen SD; Klos A; Johswich KO
mBio; 2018 Jan; 9(1):. PubMed ID: 29362231
[TBL] [Abstract][Full Text] [Related]
36. Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease.
Wang Y; Rollins SA; Madri JA; Matis LA
Proc Natl Acad Sci U S A; 1995 Sep; 92(19):8955-9. PubMed ID: 7568051
[TBL] [Abstract][Full Text] [Related]
37. Protective effect of a germline, IL-17-neutralizing antibody in murine models of autoimmune inflammatory disease.
Dallenbach K; Maurer P; Röhn T; Zabel F; Kopf M; Bachmann MF
Eur J Immunol; 2015 Apr; 45(4):1238-47. PubMed ID: 25545966
[TBL] [Abstract][Full Text] [Related]
38. A novel C5a-neutralizing mirror-image (l-)aptamer prevents organ failure and improves survival in experimental sepsis.
Hoehlig K; Maasch C; Shushakova N; Buchner K; Huber-Lang M; Purschke WG; Vater A; Klussmann S
Mol Ther; 2013 Dec; 21(12):2236-46. PubMed ID: 23887360
[TBL] [Abstract][Full Text] [Related]
39. Active immunization against IL-23p19 improves experimental arthritis.
Ratsimandresy RA; Duvallet E; Assier E; Semerano L; Delavallée L; Bessis N; Zagury JF; Boissier MC
Vaccine; 2011 Nov; 29(50):9329-36. PubMed ID: 22008816
[TBL] [Abstract][Full Text] [Related]
40. The interaction between C5a and both C5aR and C5L2 receptors is required for production of G-CSF during acute inflammation.
Bosmann M; Haggadone MD; Zetoune FS; Sarma JV; Ward PA
Eur J Immunol; 2013 Jul; 43(7):1907-13. PubMed ID: 23575697
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
